Inventiva Pharma

Clinical trials sponsored by Inventiva Pharma, explained in plain language.

Inventiva Pharma IVA NASDAQ

A biopharmaceutical company focused on fibrosis and metabolic diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Not yet finished but already full! 1 Completed 1

New drug may reverse liver damage in NASH patients

Disease control Ongoing

This study tests a drug called lanifibranor in 1000 adults with NASH (a fatty liver disease) and moderate liver scarring (stages F2 or F3). The goal is to see if the drug can reverse the scarring and reduce liver inflammation over 72 weeks. Participants are randomly assigned to r…

Phase 3 • Sponsor: Inventiva Pharma • Aim: Disease control

Last updated Jul 04, 2026 00:00 UTC

Inventiva Pharma

New drug may reverse liver damage in NASH patients